Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogensInfex to present results from Phase IIa trial for first-in-class anti-virulence therapy RESP-X at ATS 2026
The News Flicker
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogensInfex to present results from Phase IIa trial for first-in-class anti-virulence therapy RESP-X at ATS 2026
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogensInfex to present results from Phase IIa trial for first-in-class anti-v…
Originally published by GlobeNewswire. Read the full article →
More from World News
Ambuja Cements to invest $1.5 bn to lift capacity to 155 MTPA by FY30
The expansion plan comes days after Ambuja reported a 34.7% fall in quarterly net profit, hurt by higher fuel and freight costs
The News Flicker·November 2, 2026
Ambuja Cements plans ₹14,500-crore expansion to boost capacity to 155 mtpa
The expansion comes amid rising infrastructure and housing demand, with cement makers investing in plants and grinding units across regional markets.
The News Flicker·November 2, 2026
ET Product of the Year Awards 2026: Categories recognising products driving market impact
The Economic Times Product of the Year Awards 2026 celebrate cutting-edge innovations that make a substantial difference in the market and attract customer loyalty across diverse industries. Categories feature Enterprise SaaS, FinTech, Cybersecurity, as well …
The News Flicker·November 2, 2026